-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, driven by a series of policies, the development of domestic innovative drugs has accelerated significantly
.
But at the same time, companies are also facing more and more market pressure, for example, the R&D cost of innovative drugs is getting higher and higher, and the trend of medical precision is becoming more and more obvious, which makes the restriction of single indication of products more and more subdivided
.
In this context, coupled with the market pressure brought by centralized procurement, many pharmaceutical companies have begun to choose to turn their attention to overseas markets
.
At present, more and more companies have begun to embark on the road of internationalization, including local companies such as Hengrui Medicine, BeiGene, and Innovent Bio, as well as emerging drugs such as Tianjing Bio, Ruige Medicine, and Clover Bio.
Enterprise
.
With the efforts of many pharmaceutical companies, some data show that in 2021, the overseas authorization transactions of domestic innovative pharmaceutical companies, namely License out, will continue to set off a climax
.
According to incomplete statistics, there will be 53 license outs to overseas companies in China's pharmaceutical industry in 2021, far exceeding the 24 in 2020
.
At present, on the whole, cooperation with other companies, especially large multinational pharmaceutical companies, is a common way for Chinese pharmaceutical companies to go overseas
.
They may authorize clinical development and commercialization rights of innovative drugs to other pharmaceutical companies, or jointly develop new drugs
.
For example, in January 2021, BeiGene and Novartis reached a cooperation and licensing agreement on the development, production and commercialization of its self-developed PD-1 antibody drug tislelizumab in multiple countries, with a total transaction value of more than 2.
2 billion dollars
.
In August, Rongchang Bio and Seattle Gene reached a cooperation on the development and commercialization of the new ADC drug Vidicitumab in some overseas markets, with a price of US$2.
6 billion
.
The time has come to 2022, and the trend of accelerating the export of this domestic drug to the sea is still emerging
.
It is reported that in January, Junshi Bio announced that Coherus BioSciences, Inc.
(“Coherus”) has initiated the procedure to exercise the license option of TIGIT monoclonal antibody JS006 in the United States and Canada
.
At the same time, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, as well as an 18% sales share of net product sales
.
The ever-rising amount and number of cooperation shows the increasing value of these pharmaceutical companies in the global market
.
The industry predicts that in the future, with the improvement of the strength of China's innovative drug companies, the layout of more companies will no longer be limited to the domestic market, and more innovative drugs will bravely go overseas
.
However, it should be noted that going to sea is not an easy task
.
While pharmaceutical companies see opportunities to go overseas, the industry also points out that not all pharmaceutical companies can go overseas successfully
.
From the perspective of industry insiders, Chinese pharmaceutical companies need to further strengthen their intellectual property layout, overseas clinical execution capabilities, overseas commercialization layout capabilities, and global business expansion
.
In addition, overseas market development is difficult and requires high investment, which is also a big test for enterprises' resource utilization efficiency
.
Therefore, local innovative drugs still need to face various considerations such as quality and strategy, and may enter the stage of big waves in the future
.
However, in the long run, with the continuous improvement of research and development capabilities, the internationalization of China's innovative drugs will be an inevitable process
.
Overall, it will benefit the development of the domestic innovative drug industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
But at the same time, companies are also facing more and more market pressure, for example, the R&D cost of innovative drugs is getting higher and higher, and the trend of medical precision is becoming more and more obvious, which makes the restriction of single indication of products more and more subdivided
.
In this context, coupled with the market pressure brought by centralized procurement, many pharmaceutical companies have begun to choose to turn their attention to overseas markets
.
At present, more and more companies have begun to embark on the road of internationalization, including local companies such as Hengrui Medicine, BeiGene, and Innovent Bio, as well as emerging drugs such as Tianjing Bio, Ruige Medicine, and Clover Bio.
Enterprise
.
With the efforts of many pharmaceutical companies, some data show that in 2021, the overseas authorization transactions of domestic innovative pharmaceutical companies, namely License out, will continue to set off a climax
.
According to incomplete statistics, there will be 53 license outs to overseas companies in China's pharmaceutical industry in 2021, far exceeding the 24 in 2020
.
At present, on the whole, cooperation with other companies, especially large multinational pharmaceutical companies, is a common way for Chinese pharmaceutical companies to go overseas
.
They may authorize clinical development and commercialization rights of innovative drugs to other pharmaceutical companies, or jointly develop new drugs
.
For example, in January 2021, BeiGene and Novartis reached a cooperation and licensing agreement on the development, production and commercialization of its self-developed PD-1 antibody drug tislelizumab in multiple countries, with a total transaction value of more than 2.
2 billion dollars
.
In August, Rongchang Bio and Seattle Gene reached a cooperation on the development and commercialization of the new ADC drug Vidicitumab in some overseas markets, with a price of US$2.
6 billion
.
The time has come to 2022, and the trend of accelerating the export of this domestic drug to the sea is still emerging
.
It is reported that in January, Junshi Bio announced that Coherus BioSciences, Inc.
(“Coherus”) has initiated the procedure to exercise the license option of TIGIT monoclonal antibody JS006 in the United States and Canada
.
At the same time, Coherus will pay Junshi Biotechnology an upfront payment of $35 million, development, filing and sales milestone payments of up to $255 million, as well as an 18% sales share of net product sales
.
The ever-rising amount and number of cooperation shows the increasing value of these pharmaceutical companies in the global market
.
The industry predicts that in the future, with the improvement of the strength of China's innovative drug companies, the layout of more companies will no longer be limited to the domestic market, and more innovative drugs will bravely go overseas
.
However, it should be noted that going to sea is not an easy task
.
While pharmaceutical companies see opportunities to go overseas, the industry also points out that not all pharmaceutical companies can go overseas successfully
.
From the perspective of industry insiders, Chinese pharmaceutical companies need to further strengthen their intellectual property layout, overseas clinical execution capabilities, overseas commercialization layout capabilities, and global business expansion
.
In addition, overseas market development is difficult and requires high investment, which is also a big test for enterprises' resource utilization efficiency
.
Therefore, local innovative drugs still need to face various considerations such as quality and strategy, and may enter the stage of big waves in the future
.
However, in the long run, with the continuous improvement of research and development capabilities, the internationalization of China's innovative drugs will be an inevitable process
.
Overall, it will benefit the development of the domestic innovative drug industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
